Latest News and Press Releases

Results of IMNN-101 Proof-of-Concept study demonstrate persistent immunogenicity in trial participants and further validate PlaCCine® technology IMNN-101 induced 2- to 4-fold increase in neutralizing...

Dublin, Feb. 04, 2025 (GLOBE NEWSWIRE) -- The "Aplastic Anemia - Global Clinical Trials Review, 2024" report has been added to ResearchAndMarkets.com's offering.The clinical trial report provides...

HUNTSVILLE, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company, today announced the successful closing of the second...

HUNTSVILLE, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company, today announced a $10 million equity financing with...

Pasithea Tx' PAS-004 Phase 1 trial advances to a 15mg dose after no toxicities or rash observed, highlighting its safety and differentiated profile.

Targeting Transformative Solutions for Aplastic Anemia and Beyond SAN DIEGO, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC Pink: RGBP and RGBPP) today provided further insight into...

Pasithea Therapeutics' PAS-004 shows positive Phase 1 data: well-tolerated, no toxicities, promising efficacy in NF1 and MAPK-driven cancers.

Pasithea Therapeutics completes enrollment and initial dosing of Cohort 2 in its Phase 1 trial of PAS-004, with interim safety data expected in Q3 2024.

Dublin, June 07, 2024 (GLOBE NEWSWIRE) -- The "Global GPRC5D Targeting Drugs Market Opportunity and Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering. In...

Dublin, Nov. 21, 2023 (GLOBE NEWSWIRE) -- The "US Clinical Trial Data Management Service Market - Focused Insights 2023-2028" report has been added to ResearchAndMarkets.com's offering. The US...